HC Wainwright Raises Liquidia (NASDAQ:LQDA) Price Target to $35.00

Liquidia (NASDAQ:LQDA) had its price target hoisted by HC Wainwright from $29.00 to $35.00 in a report released on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. HC Wainwright’s target price would suggest a potential upside of 133.33% from the stock’s previous close.

Several other equities research analysts have also weighed in on LQDA. Oppenheimer set a $13.00 price target on Liquidia and gave the stock an “underperform” rating in a research note on Monday, May 19th. Wall Street Zen raised shares of Liquidia from a “sell” rating to a “hold” rating in a research report on Thursday, May 22nd. Needham & Company LLC reissued a “buy” rating and set a $25.00 price target on shares of Liquidia in a research report on Wednesday, May 21st. Raymond James boosted their price objective on shares of Liquidia from $27.00 to $29.00 and gave the stock a “strong-buy” rating in a research note on Friday, May 9th. Finally, Scotiabank reaffirmed an “outperform” rating on shares of Liquidia in a research note on Monday, May 5th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, six have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.67.

Liquidia Trading Up 5.8%

Shares of NASDAQ LQDA opened at $15.00 on Wednesday. The firm has a fifty day simple moving average of $14.72 and a two-hundred day simple moving average of $13.69. Liquidia has a 12 month low of $8.26 and a 12 month high of $19.41. The firm has a market capitalization of $1.28 billion, a PE ratio of -9.20 and a beta of 0.24.

Liquidia (NASDAQ:LQDA) last announced its quarterly earnings results on Thursday, May 8th. The company reported ($0.45) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by ($0.03). The company had revenue of $3.12 million for the quarter, compared to analysts’ expectations of $3.23 million. Liquidia had a negative net margin of 765.38% and a negative return on equity of 163.21%. On average, sell-side analysts predict that Liquidia will post -1.51 earnings per share for the current year.

Insiders Place Their Bets

In other Liquidia news, insider Jason Adair sold 1,856 shares of the stock in a transaction dated Monday, April 14th. The stock was sold at an average price of $13.57, for a total transaction of $25,185.92. Following the sale, the insider now directly owns 184,304 shares of the company’s stock, valued at approximately $2,501,005.28. This trade represents a 1.00% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, insider Rajeev Saggar sold 2,450 shares of the firm’s stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $13.67, for a total value of $33,491.50. Following the sale, the insider now directly owns 263,152 shares in the company, valued at approximately $3,597,287.84. This trade represents a 0.92% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 33,138 shares of company stock worth $450,233 over the last 90 days. Company insiders own 26.50% of the company’s stock.

Institutional Trading of Liquidia

Several institutional investors have recently bought and sold shares of the business. Vanguard Group Inc. raised its position in shares of Liquidia by 3.4% during the 4th quarter. Vanguard Group Inc. now owns 3,557,296 shares of the company’s stock worth $41,834,000 after purchasing an additional 115,367 shares during the last quarter. LM Advisors LLC purchased a new stake in Liquidia during the 4th quarter worth approximately $25,948,000. Whitefort Capital Management LP raised its holdings in shares of Liquidia by 16.8% during the fourth quarter. Whitefort Capital Management LP now owns 1,987,245 shares of the company’s stock valued at $23,370,000 after acquiring an additional 285,220 shares during the last quarter. Vestal Point Capital LP raised its holdings in shares of Liquidia by 17.3% during the fourth quarter. Vestal Point Capital LP now owns 1,760,000 shares of the company’s stock valued at $20,698,000 after acquiring an additional 260,000 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Liquidia by 8.2% in the fourth quarter. Geode Capital Management LLC now owns 1,339,254 shares of the company’s stock valued at $15,753,000 after acquiring an additional 101,597 shares in the last quarter. 64.54% of the stock is owned by institutional investors and hedge funds.

About Liquidia

Liquidia Corporation, a biopharmaceutical company, develops, manufactures, and commercializes various products for unmet patient needs in the United States. Its lead product candidates include YUTREPIA, an inhaled dry powder formulation of treprostinil for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD).